Ir.aegerion.com

Ir Aegerion. The Investor Relations website contains information about Novelion Therapeutics's business for stockholders, potential investors...

Never miss Ir.aegerion.com updates: Start reading the news feed of Ir Aegerion right away! This site’s feed is stale or rarely updated (or it might be broken for a reason), but you may check related news or Ir.aegerion.com popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to Ir Aegerion

Subscribe to related news

Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Completion of Acquisition or Disposition of Assets
via marketexclusive

Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Completion of Acquisition or Disposition of Assets Item 2.01. Completion of Acquisition or Disposition of Assets. On November29, 2016, to the terms of the Agreement and Plan of Merger, dated as...
Aegerion Pharmaceuticals, a Subsidiary of Novelion Therapeutics, Enters into Agreement in Principle to Settle Class Acti...
via investingnews

Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (the “Company”), today announced that on December 3, 2016, Aegerion Pharmaceuticals...
QLT and Aegerion Pharma to merge
via biotuesdays

QLT (NASDAQ:QLTI; TSX:QLT) and Aegerion Pharmaceuticals (NASDAQ:AEGR) have entered into a definitive merger agreement, with the resulting company to be renamed, Novelion Therapeutics. Under the accord, each outstanding share of Aegerion common stock...
Aegerion Pharmaceuticals Announces Second Quarter 2015 Financial Results
via military-technologies

– Company records $64.2 million in total net product sales –– JUXTAPID® net product sales were $57.1 million in the second quarter of 2015, 96% from prescriptions written in the U.S. –– Company reiterates 2015 total net product sales guidance of between...
JUXTAPID, New Treatment for HoFH Approved
via elbiruniblogspotcom.blogspot

JUXTAPID, New Treatment for HoFH Approved New Treatment for HoFH Approved Dec 24 2012 CAMBRIDGE, Mass., Dec. 24, 2012 (GLOBE NEWSWIRE) — Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization...

Ir.aegerion.com popular pages

Investors - Novelion Therapeutics Inc.

The Investor Relations website contains information about Novelion Therapeutics Inc. business for stockholders, potential investors, and financial analysts.
Investors - Novelion Therapeutics Inc.

The Investor Relations website contains information about Novelion Therapeutics Inc. business for stockholders, potential investors, and financial analysts....

Investors - Novelion Therapeutics Inc.

Investors Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of...